- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07610512
Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines
A Prospective Study to Determine the Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccine Recipients Study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Large-scale clinical trials have demonstrated that COVID-19 vaccines effectively reduce the incidence of COVID-19, as well as the risk of severe disease and mortality. These protective effects are primarily mediated through vaccine-induced immune responses, including both humoral immunity (antibody production) and cellular immunity.
Probiotics are widely recognized for their potential health benefits and are commonly consumed in foods such as yogurt. Emerging evidence suggests that probiotic supplementation may enhance immune responses to vaccination, as demonstrated in studies involving influenza vaccines.
This study is designed to investigate whether oral probiotic supplementation can modulate the immune response to COVID-19 vaccination. The study will evaluate both antibody responses and cellular immune responses following vaccination, and assess whether probiotics can enhance or accelerate the development of vaccine-induced immunity. In addition, the study will explore whether probiotic supplementation may reduce vaccine-related adverse effects.
A total of 140 participants are planned to be enrolled in this study.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Taipei, Taïwan
- Taipei Medical University Hospital.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Male or female subject ≥ 20 to ≤ 65 years of age at the time signing informed consent form.
- Body weight ≥50 kgs
- Must be scheduling to receive a BNT162b2 mRNA COVID-19 vaccine
- Being able to comply with the study protocol
- Being able to independently provide written informed consent
Exclusion Criteria:
- Taking antibiotic at enrollment
- Taking immunomodulatory (e.g., steroid) or anti-histamine drugs
- Took pre- or probiotics within the past 30 days
- Being to expected to take other probiotic supplement during the study period
- Being expected to take antibiotic during the study period
- A history of hypersensitivity or severe allergic reaction to any components of the probiotics or placebo supplement
- Pregnant or breastfeeding
- Having a severe immunocompromised disorder (e.g. HIV infection)
- Solid organ or bone marrow transplant recipients
- Major gastrointestinal surgery within 3 months before enrollment
- Having severe active gastrointestinal conditions, including inflammatory bowel disease or diverticulitis
- No self-reported symptoms of an upper airway infection with the past 2 weeks
- A history of SARS-CoV-2 infection
- Previously participated in investigational study involving SARS-CoV-2 vaccines or therapies
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Probiotic Group
Participants will receive oral probiotic capsules containing Lactobacillus spp.
once daily for 4-5 weeks following COVID-19 vaccination.
The intervention is administered to evaluate the immunomodulatory effects of probiotics on vaccine-induced humoral and cellular immune responses.
|
Oral probiotic capsules containing Lactobacillus spp.
administered once daily for 4-5 weeks following COVID-19 vaccination to evaluate immunomodulatory effects on vaccine-induced immune responses.
Autres noms:
|
|
Comparateur placebo: Placebo Group
Participants will receive matching placebo capsules containing microcrystalline cellulose once daily for 4-5 weeks following COVID-19 vaccination.
The placebo is identical in appearance, packaging, and administration schedule to the probiotic capsules.
|
Matching placebo capsules containing microcrystalline cellulose administered once daily for 4-5 weeks following COVID-19 vaccination.
The placebo is identical in appearance, packaging, and schedule to the probiotic capsules.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
SARS-CoV-2 spike protein-specific IgG antibody level
Délai: Baseline (Day 0-7 before vaccination), Day 14 (±4 days), and Day 28 (±4 days) after first dose of BNT162b2 vaccination
|
Change in SARS-CoV-2 spike protein-specific IgG antibody levels following COVID-19 vaccination between probiotic and placebo groups.
|
Baseline (Day 0-7 before vaccination), Day 14 (±4 days), and Day 28 (±4 days) after first dose of BNT162b2 vaccination
|
|
SARS-CoV-2-specific T cell immune response at Day 14 after vaccination.
Délai: Baseline and Day 14 (±4 days) after vaccination
|
Assessment of vaccine-induced cellular immune response measured by antigen-specific T cell activation between probiotic and placebo groups.
|
Baseline and Day 14 (±4 days) after vaccination
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Infections des voies respiratoires
- Infections
- Infections par virus à ARN
- Maladies virales
- Maladies des voies respiratoires
- Maladies pulmonaires
- Pneumonie virale
- Pneumonie
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- COVID-19 [feminine]
- Suppléments alimentaires
- Nourriture
- Régime, nourriture et nutrition
- Phénomènes physiologiques
- Nourriture et boissons
- Probiotiques
- Lactteol
Autres numéros d'identification d'étude
- N202109037
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .